Stanford University researchers have again found that low-dose naltrexone (LDN) is a beneficial treatment for fibromyalgia.
The new study, just published in Arthritis and Rheumatism, aimed to confirm and expand Stanford's earlier research on LDN. It's small and still considered preliminary, but continued positive outcomes of this kind are necessary for moving up to larger studies.
In this study, participants taking LDN had:
- 28% reduction in pain
- Improved satisfaction with life
- Improved mood
- NO improvement in fatigue or sleep
- NO serious side effects
Especially good news for people with fibromyalgia, who are often especially prone to side effects, is that LDN was tolerated just as well as a placebo.
- Learn More: Low-Dose Naltrexone
LDN is an inexpensive, widely available medication with a long record of being safe and well tolerated. If positive results continue through larger trials, it could become an excellent option for people with fibromyalgia. As is, some doctors are willing to prescribe it, but many are likely to be reluctant until we have more data.